OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
This article was originally published in The Tan Sheet
Executive Summary
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
You may also be interested in...
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
FDA’s OPaSS promotion
Deputy Director of the Office of Pharmacoepidemiology & Statistical Science (OPaSS) will be Jonca Bull, MD, FDA states May 2; the announcement is effective immediately. OPaSS Director Paul Seligman, MD, said Bull "will be responsible for the development and implementation of many of the drug safety and statistical strategic initiatives in OPaSS, in addition to assisting me with the management of the office." She most recently served as director of Office of Drug Evaluation V, which is being eliminated as part of CDER's reorganization (1"The Tan Sheet" Oct. 25, 2004, p. 3)...
FDA Office Of New Drug Restructuring To Include OTC Resource Reallocation
FDA's Office of New Drugs restructuring will more efficiently allocate the agency's resources and staff, particularly with respect to OTCs, Director John Jenkins, MD, said